Ask AI
ProCE Banner Activity

Phase II Study of Lenacapavir, Teropavimab, and Zinlirvimab in People Living With Virologically Suppressed HIV: Wk 52 Results

Conference Coverage
Slideset

In this trial, 89% of patients who switched from a virally suppressive oral ART regimen to lenacapavir, teropavimab, and zinlirvimab administered every 6 months maintained viral suppression through 52 weeks, with the majority expressing a preference for the long-acting regimen vs daily oral ART.

Released: October 23, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare